3 completed, 1 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow nangibotide: new trials by email Literature Review of nangibotide trials Research Report on nangibotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support nangibotide, placebo - COVID19 | Phase 2 | Completed | Inotrem | 220 | 2020-09-23 | 2023-05-03 |
| Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock nangibotide low dose, nangibotide high dose, placebo - Shock, Septic | Phase 2 | Active not recruiting | Inotrem | 355 | 2019-11-13 | 2023-04-11 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock Nangibotide 0.3 mg/kg, Placebo, Nangibotide 1 mg/kg - Shock, Septic | Phase 2 | Completed | Inotrem | 50 | 2017-07-03 | 2024-10-08 |
| Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects nangibotide, Placebo - Healthy Subjects | Phase 1 | Completed | Inotrem | 27 | 2016-04-01 | 2025-02-10 |
Shock, Septic (2) · COVID-19 (1) · Sepsis (1)
Inotrem (4)
Belgium (3) · France (3) · Spain (2) · Denmark (1) · Finland (1) · Ireland (1) · Netherlands (1) · United Kingdom (1)
PMID 29885068, PMID 34233965, PMID 37269870, PMID 37350989
2018 (1)